Literature DB >> 9848349

Acute parvovirus B19 infection associated with fulminant hepatitis of favourable prognosis in young children.

E M Sokal1, M Melchior, C Cornu, A T Vandenbroucke, J P Buts, B J Cohen, G Burtonboy.   

Abstract

BACKGROUND: The cause of fulminant hepatitis (FH) in children is unexplained in up to 50% of cases. We report parvovirus B19 as an agent associated with FH in children and compare clinical characteristics of these patients with those of age-matched patients with FH of other origin.
METHODS: 45 patients presented with FH. No cause was apparent in 21 patients. Parvovirus B19 genome was retrospectively sought by PCR in serum collected at admission in 41 patients.
FINDINGS: Parvovirus B19 genome was detected in serum from four of 21 patients with unexplained FH (four of 11 younger than 5 years). No B19 DNA was detected in serum from patients with other types of FH or from 82 patients with biliary atresia. Parvovirus B19 IgM was detected in one of the four patients. Patients with parvovirus B19 infection had significantly lower bilirubin concentrations than age-matched patients with FH due to hepatitis A (nine) or other causes (nine) (poisoning with amanita excluded). All patients with parvovirus B19 survived without orthotopic liver transplantation, with restoration of normal liver function within 17 days.
INTERPRETATION: In patients younger than 5 years with FH of unexplained origin, evidence of acute parvovirus B19 was associated with a distinct clinical pattern. In particular, low bilirubin concentrations and rapid recovery of liver function without transplantation were distinctive features.

Entities:  

Mesh:

Year:  1998        PMID: 9848349     DOI: 10.1016/S0140-6736(98)06165-0

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  21 in total

Review 1.  Pathogenesis of human parvovirus B19 in rheumatic disease.

Authors:  J R Kerr
Journal:  Ann Rheum Dis       Date:  2000-09       Impact factor: 19.103

2.  Acute fulminant hepatic failure associated with parvovirus B19 infection in an immunocompetent adult.

Authors:  Robert J Huang; Brandon C Varr; George Triadafilopoulos
Journal:  Dig Dis Sci       Date:  2012-03-07       Impact factor: 3.199

3.  Acute hepatitis as a manifestation of parvovirus B19 infection.

Authors:  Aleisha Hatakka; Julianne Klein; Runtao He; Jessica Piper; Edward Tam; Andrew Walkty
Journal:  J Clin Microbiol       Date:  2011-07-06       Impact factor: 5.948

Review 4.  Evolutionary aspects of Parvovirus B-19V associated diseases and their pathogenesis patterns with an emphasis on vaccine development.

Authors:  Piyanki Das; Koustav Chatterjee; Nabanita Roy Chattopadhyay; Tathagata Choudhuri
Journal:  Virusdisease       Date:  2019-03-26

5.  Role of erythropoietin receptor signaling in parvovirus B19 replication in human erythroid progenitor cells.

Authors:  Aaron Yun Chen; Wuxiang Guan; Sai Lou; Zhengwen Liu; Steve Kleiboeker; Jianming Qiu
Journal:  J Virol       Date:  2010-09-22       Impact factor: 5.103

6.  Down-regulation of inwardly rectifying Kir2.1 K+ channels by human parvovirus B19 capsid protein VP1.

Authors:  Musaab Ahmed; Bernat Elvira; Ahmad Almilaji; C-Thomas Bock; Reinhard Kandolf; Florian Lang
Journal:  J Membr Biol       Date:  2014-12-09       Impact factor: 1.843

7.  Characterization of erythrovirus B19 genomes isolated in liver tissues from patients with fulminant hepatitis and biliary atresia who underwent liver transplantation.

Authors:  Kenji Abe; Tetsuya Kiuchi; Koichi Tanaka; Yoshihiro Edamoto; Naoto Aiba; Tetsutaro Sata
Journal:  Int J Med Sci       Date:  2007-04-05       Impact factor: 3.738

Review 8.  Viral myocarditis: from experimental models to molecular diagnosis in patients.

Authors:  Sabine Pankuweit; Karin Klingel
Journal:  Heart Fail Rev       Date:  2013-11       Impact factor: 4.214

Review 9.  [Viral exanthem].

Authors:  R Fölster-Holst
Journal:  Hautarzt       Date:  2004-09       Impact factor: 0.751

Review 10.  Human parvovirus B19.

Authors:  Erik D Heegaard; Kevin E Brown
Journal:  Clin Microbiol Rev       Date:  2002-07       Impact factor: 26.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.